Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia 6Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Recurrence × Homoharringtonine × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital

Phase 3 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡